Lifecore Biomedical (LFCR) Projected to Post Quarterly Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) will likely be issuing its quarterly earnings data on Thursday, April 3rd. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $33.23 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Trading Up 2.8 %

Lifecore Biomedical stock opened at $7.04 on Tuesday. Lifecore Biomedical has a one year low of $3.68 and a one year high of $7.99. The company’s fifty day moving average price is $6.15 and its two-hundred day moving average price is $6.22. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The company has a market capitalization of $260.66 million, a price-to-earnings ratio of -12.57 and a beta of 0.96.

Insider Buying and Selling

In other Lifecore Biomedical news, CEO Paul Josephs bought 17,000 shares of the stock in a transaction on Wednesday, January 8th. The shares were purchased at an average price of $5.74 per share, with a total value of $97,580.00. Following the acquisition, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at $3,212,775.58. This represents a 3.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 32.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, Stephens reissued an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.